Heat Biologics, Inc.: Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110

07:08 EDT 18 Apr 2018 | FinanzNachrichten

- Plans Interim Lung Cancer Phase 2 Readout in Q4 2018 and Final Readout in Q2 2019 - Expects to File IND and Enroll First Patient in ComPACT Trial in Q4 2018 - Anticipates Receipt of $6.9 Million ...

More From BioPortfolio on "Heat Biologics, Inc.: Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110"